Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,500
+450 (1.95%)
At close: Feb 27, 2026
Market Cap1.05T +584.7%
Revenue (ttm)46.65B +529.9%
Net Income16.75B
EPS1,513.84
Shares Out44.89M
PE Ratio15.52
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,086,104
Average Volume1,618,934
Open23,850
Previous Close23,050
Day's Range22,700 - 24,450
52-Week Range3,138 - 28,900
Betan/a
RSI62.24
Earnings DateMar 13, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements